TEK and colorectal cancer: The findings are of considerable interest as (i) they are mechanistically plausible given the interaction between VEGF and Angiopoietin signaling pathways;4,5 (ii) VEGFi-induced pharmacodynamic changes in Tie2 have been observed in glioma2, gall bladder6, and colorectal cancer;3 and (iii) the Ang/Tie2 pathway is a known and valid clinical target in colorectal7 and ovarian cancer8–10.